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461* Clinical features of a cystic ﬁbrosis patient chronically colonized
with Pandoraea pnomenusa identiﬁed using MALDI-TOF mass
spectrometry
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Data from the clinical course and outcome of CF patients colonized/infected with
Pandoraea spp. are scarce, partially due to the difﬁculties in its identiﬁcation.
MALDI-TOF MS (MT) has been recently introduced for Clinical Microbiology use
improving bacterial identiﬁcation.
Objetive: To describe the clinical features of a patient, chronically colonized along
3 years with Pandoraea pnomenusa, after re-examination of bacterial identiﬁcation
results.
Methods: Eight isolates recovered from sputum cultures (2006 to 2009) of a
28-year-old female patient were re-identiﬁed using MT (MALDI BioTyper 2.0,
Bruker Daltonik, Germany). PCR of 16S rDNA and sequencing were also per-
formed. Genetic relatedness of isolates was assessed (XbaI-PFGE).
Results: The patient ﬁrstly acquired P. pnomenusa in Oct-2006. Her pulmonary
function remained stable, FVC 2.87 L (85%) and FEV1 2.22 L (75%), until
Jan-2008 when her clinical condition worsens, suffering from 7 pulmonary ex-
acerbations that required antibiotic treatment. Her lung function declined to FVC
2.36 L (72%) and FEV1 1.85 L (65%) (Oct-2009). Laboratory records indicated that
8 isolates were identiﬁed, by conventional methods, as various “non-fermentative
Gram-negative bacilli”. MT identiﬁed all these isolates as P. pnomenusa. PCR
of 16S rDNA and sequencing could establish the genus. PFGE results revealed
indistinguishable patterns.
Conclusions: The presence of Pandoraea spp. can be underestimated in CF patients
when using conventional identiﬁcation methods. MT provides an accurate identi-
ﬁcation of this organism which may have a potential role in pulmonary function
deterioration when chronically colonizes CF patients.
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I. is a 22-year-old female affected by cystic ﬁbrosis, diagnosed at birth for the
presence of meconium ileus. She also suffers from CF related diabetes and mild CF
hepatopathy. Since 2003 B. cenocepacia was constantly isolated from her sputum. In
January 2009 she had a respiratory exacerbations with increased sputum production,
increased dyspnoea and decreased FEV1 (from 48% to 36% of predicted at admis-
sion) requiring a course of intravenous antibiotics. Laboratory tests at admission
shown increased erythrocyte sedimentation rate (ESR 66mm/h) and C-reactive
protein (CPR 5.56mg/dl). Last available sputum culture of B. cenocepacia was
resistant to all commonly used antibiotics. While awaiting multiple combination
bactericidal antibiotic test results, IV meropenem, tobramicin and ceftazidime were
administered. After four days of therapy her clinical condition began to deteriorate,
with increased CRP (8.73mg/dl), decreased spirometric results (FEV1 18% of
predicted), intermittent fever and increased need for oxygen supplementation (from
1 to 4 l/min). Meanwhile multiple combination tests did not prove bactericidal
activity. We decided to introduce Temocillin, an intravenous antibiotic not used
in Italy, but proven to be efﬁcacy in the treatment of B. cenocepacia multiresistant
exacerbation. From the 16th days of hospitalisation temocillin was administered.
After two days of treatment the fever disappears and CRP started to diminish
(from 9.8mg/dl to 0.5mg/dl at days 21). After two weeks of intravenous temocillin
therapy. To this days she experienced 4 more exacerbations, all successfully treated
with IV temocillin; she is currently awaiting for lung transplantation.
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FEV1< 40% of predicted value is a relative contraindication for pregnancy. Here
we introduce a 29 ys old woman who decided to carry out her pregnancy despite
a FEV1 of 25% pred. at 2 weeks’ gestation.
She had a severe bronchopneumopaty with a FEV1< 30% in past 4 ys with
chronic infection by P. Aeruginosa, MRSA. During last exacerbations, she needed
oxygen therapy (OT) at rest and during efforts. She has pancreatic insufﬁciency
but a good BMI (20) and a CFRDM insulin-dependent. Once pregnant, our
team regularly assessed clinical status, cardio-respiratory function, glucose blood
levels and microbiological ﬁndings. She required 3 hospitalizations at 17th, 26th
and 28th week’s gestation due to acute exacerbations; she was treated with i.v.
ceftazidime, inhaled colistine, steroids and OT, ﬁrst nocturnal then daytime. To
prevent respiratory deterioration and dyspnoea we started to acclimatize her to NIV
since the ﬁrst admission, with no recorded hypercapnia. Though her reluctance,
it was then well tolerated and she used it increasingly, especially during sleep.
Spirometry, SpO2 and gas exchange remained stable throughout pregnancy. A joint
decision was made to deliver the baby at 31st week gestation by caesarian section,
using spinal-anesthesia and being assisted by physiotherapists for NIV in operating
theatre. The outcome was successful for her and the newborn.
A close surveillance, a sub-continuous antibiotic therapy, a tailored respiratory
physiotherapy and a multidisciplinary work let her be in fairly good health to
give birth. According to our ﬁndings and patient’s judgment, the key point of this
success has been the early but gradual use of NIV.
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Introduction and Aim: Dehydration is a common complication of cystic ﬁbrosis.
Its frequency mainly depends on external factors as a rise in environmental
temperature, fever, excess loss and/or inadequate intake of salt and ﬂuids. As
dehydration progresses, hypovolemic shock ultimately ensues, with a detrimental
effect on the vital organs. At the present study, we aimed to explore the inﬂuence
of dehydration on kidneys of infants with cystic ﬁbrosis. Speciﬁcally, we studied
the ultrasonographic changes of kidneys after an episode of severe dehydration.
Patients and Methods: 12 infants with cystic ﬁbrosis were admitted to the hospital
with dehydration over the last year. There were 6 boys and 6 girls (mean age
17 months). All the infants were admitted during summer months (June to August).
For 4/12 dehydration was the presenting symptom of cystic ﬁbrosis. All infants
were investigated with renal ultrasound at the time of dehydration. The severity of
dehydration was correlated with ultrasound ﬁndings.
Results: 4/12 infants with cystic ﬁbrosis and dehydration had abnormal renal
ultrasound at the time of dehydration. Speciﬁcally, the ultrasound examination
demonstrated echogenic kidneys with preservation of the corticomedullary differen-
tiation. The kidneys were equally involved. All 4 children had markedly abnormal
electrolytes with chloride below 70mmol/l and urea above 100mg/dl.
Conclusion: Severe dehydration causes renal changes as detected by ultrasound
scan. It is important to take this event into consideration and avoid concomitant use
of nephrotoxic drugs, which may have an add-on effect on vulnerable kidneys and
cause irreversible damage.
